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ABSTRACT
Objectives: Vascular endothelial growth factor (VEGF) is an important angiogenic factor that regulates angiogenesis and 
mediates sex steroid-induced cell growth. The present study investigated the association of VEGF gene-2578C/A (rs699947) 
and −2549 insertion/deletion polymorphisms in the promoter region of VEGF-A gene and uterine leiomyoma susceptibility 
in Southeast of Iran. 
Material and methods: One hundred and fifty five women with uterine leiomyoma and 157 age, BMI, and ethnicity 
matched healthy women were enrolled in this study. VEGF gene –2578C/A polymorphism genotyping was performed by 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and the –2549 insertion/dele-
tion polymorphism was analyzed by PCR method. 
Results: The frequency of alleles and genotypes of VEGF-2578C/A polymorphism was not different between women with 
uterine leiomyoma and the controls; however, a significant association was revealed between II genotype of –2549 inser-
tion/deletion (I/D) polymorphism of VEGF gene and uterine leiomyoma. 
Conclusions: The findings showed that VEGF gene –2549 insertion/deletion polymorphism was associated with uterine 
leiomyoma.
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INTRODUCTION
Uterine leiomyomas (ULs) are benign and monoclonal 
tumors of the smooth muscle cells in the myometrium. It is 
estimated that the prevalence of these tumors is 77% of all 
reproductive-age women in the United States [1]. ULs are 
asymptomatic in 50–40% of women over 35 years old; how- 
ever, it could be associated with symptoms such as menorrha-
gia, pain, infertility, and recurrent pregnancy loss [2]. UL may 
affect the pregnancy in one third of women and enlarge its 
size in the first and third trimesters of pregnancy due to altered 
levels of hormones especially estrogen [3]. Different risk fac-
tors may affect UL development including: obesity, ethnicity, 
family history, diet rich in meat, smoking, age increasing, use 
of oral contraceptive pills, and biological biomarkers [4]. 
Although the exact etiology of UL is unknown, there 
are several factors influencing the growth of UL [5]. They 
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include not only ovarian steroids, angiogenesis, and growth 
factors, but also the apoptosis related factors [6]. It is well 
known that ULs respond to the ovarian hormones such 
as estrogen and progesterone, and their epidemiology 
parallels the ontogeny and life-cycle changes in genital 
hormones [7].
Several studies have shown that different growth factors 
such as epidermal growth factor (EGF), insulin-like growth 
factors I and II (IGF-I/IGF-II), VEGF, transforming growth 
factor-beta (TGF-β), platelet-derived growth factor (PDGF), 
and basic fibroblast growth factor (bFGF), which are the me-
diators of cell proliferation, increase the extracellular matrix 
and hypertrophy involved in UL [8, 9]. VEGF is an angiogenic 
peptide that plays an important role in the growth of nu-
merous tumors [10, 11]. Amongst seven different types of 
VEGF (VEGF-A, -B, -C, -D, -E, -F, and placental growth factor), 
VEGF-A and B are mostly angiogenic [12, 13].
VEGF binds to VEGF receptors (VEGFR-1 and VEGFR-2) on 
endothelial cells, triggering a Tyrosine Kinase pathway lead-
ing to angiogenesis. VEGF expression is potentiated by a vari-
ety of cytokine and hormones [13]. The human VEGF-A gene 
is located on chromosome 6 (6p12.1) and contains a 14-kb 
coding region with eight exons and seven introns [14, 15]. 
There are numerous VEGF polymorphisms, some of which 
are associated with altered VEGF expression [16]. A num-
ber of genetic studies have revealed the association be-
tween UL development and genetic polymorphisms; for 
example, VEGF [17], estrogen receptors [18, 19], XRCC1 and 
p53 [20], CYP1A1 [21], Catechol-O-methyl transferase [22] 
and MDM2 [23] genes.
Although there is one report about the relation be-
tween VEGF  gene 5’-UTR –460 polymorphism and UL, 
there is no published report about the association be-
tween-2578C/A (rs699947) and −2549 insertion/deletion 
polymorphisms of VEGF gene and UL susceptibility.
The current study aimed to evaluate the association 
between –2578C/A (rs699947) and −2549 insertion/dele-
tion polymorphisms in the promoter region of VEGF gene 
and UL susceptibility.
MATERIAL AND METHODS
This study was performed on 155 women with UL 
(aged 38.5 ± 9.7 years) and 157 healthy women (aged 
38.4 ± 7.9 years) as controls without any systematic disease, 
homogenous with the patient group (age, race, and BMI). 
The study protocol was approved by the Ethics Commit-
tee of Zahedan University of Medical Sciences, and all the 
patients granted their informed consent.
Samples containing 2 mL of peripheral blood were taken 
from all women for genetic analysis. They were poured in 
tubes containing EDTA and stored at –20ºC.
Genotype analysis 
Genomic DNA was extracted from EDTA treated whole 
blood through salting out method. VEGF polymorphisms 
genotyping was performed by polymerase chain reaction-re-
striction fragment length polymorphism method (PCR-RFLP). 
The fragment containing VEGF-2578 C/A polymorphism 
was amplified, using forward; 5'-GGATGGGGCTGACTAG-
GTAAGC-3' and reverse; 5'-AGCCCCCTTTTCCTCCAAC-3' 
primers. The target fragment containing −2549 inser-
tion/deletion polymorphism was amplified using forward; 
5’-CCTGGAGCGTTTTGGTTAAA-3’ and reverse; 5’-ATATAG-
GAAGCAGCTTGGAA-3’ primers.
The PCR conditions were set as follows: one cycle at 
95°C for 5 min, 30 cycles at 95°C for 20 s, annealing respec-
tively at 58°C and 62°C for 30 s and 2 min (VEGF C-2578A 
and−2549 insertion/deletion), and extension at 72°C for 45 s, 
and a final extension cycle at 72°C for 5 min. The 325bp-
PCR product of –2578C/A polymorphism was digested with 
2-U BglII restriction enzyme (Fermentas, Vilnius, Lithuania) 
at 37°C overnight. Digested products were electrophoresed 
on 2% agarose gel containing ethidium bromide. The C 
allele of C-2578A had no BglII cleavage site, whereas in 
presence of A allele 325 bp fragment cleaved to 202 and 
123 bp fragments.
The PCR product of −2549 insertion/deletion polymor-
phism was loaded into 3% agarose gel containing ethidium 
bromide for electrophoresis. I and D alleles of VEGF I/D poly-
morphism produced 234bp and 216 bp bands, respectively.
Statistical analysis
Statistical analyses were performed using SPSS 
V-20. Clinical and demographic characteristics of UL women 
and control groups were compared by the independent stu-
dent’s t-test or Fisher’s exact test whenever appropriate. The 
alleles and genotypes’ frequencies between the groups (pa-
tients and controls) were compared applying Fisher’s exact 
test. To determine the effect of polymorphisms on the risk of 
UL Logistic Regression analysis was used. p-value < 0.05 was 
considered statistically significant.
RESULTS
Clinical and demographic characteristics of UL women 
and control group are given in Table 1. The maternal age 
and menarche age were not statistically different between 
two groups. The frequency of bleeding and pain were sig-
nificantly higher in the UL group compared to the controls.
Alleles and genotypes frequency of VEGF-2578C/A poly-
morphism is presented in Table 2. VEGF-2578C/A polymor-
phism was in Hardy-Weinberg equilibrium in both groups 
(p > 0.05). There was no association between genotypes of 
the VEGF-2578C/A polymorphism and UL susceptibility. In 
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addition, the frequency of VEGF-2578C/A alleles was not 
different between two groups.
Alleles and genotypes’ frequency of VEGF −2549 inser-
tion/deletion polymorphism is presented in Table 3. The 
frequency of II genotype of VEGF −2549 insertion/deletion 
polymorphism was significantly higher than DD genotype in 
UL women compared to controls (25 vs. 12 %), and the risk 
of UL was 1.5 fold higher in presence of II genotype ([OR, 1.5 
[95% CI, 1–2.1]; p = 0.03).
Moreover, the risk of UL was 2.4 fold higher in women with 
II genotype compared to DD + ID genotypes (recessive model) 
([OR, 2.4 [95% CI, 1.3–4.3]; p = 0.004). The frequency values 
of I and D alleles were not different between two groups.
DISCUSSION
In the present study, two polymorphisms of VEGF gene 
in UL women and controls were evaluated. The findings 
showed no association between VEGF-2578C/A (rs699947) 
polymorphism and UL; however, a significant association 
was revealed between II genotype of −2549 insertion/dele-
tion (I/D) polymorphism of VEGF gene and UL in Southeast 
Iranian women.
UL is the most common tumor in women; however, 
its molecular etiology is still unknown. Many hormones 
and cytokines are associated with leiomyoma formation, 
including progesterone, estrogen, insulin-like growth factor, 
fibroblast growth factor, epidermal growth factor and VEGF. 
VEGF, as an endothelial cell specific regulator, is a key factor 
influencing tumor related angiogenesis. Several studies 
showed that over expression of VEGF might be related to 
numerous tumors, including endometrial cancer [24], breast 
cancer [25], hepatocellular carcinoma, and UL [26].
Considering the importance of VEGF in angiogenesis, the 
association of VEGF polymorphisms and various tumors has 
been investigated. Nevertheless, there is only one report on 
the association of VEGF-460 polymorphism in 5'-untranslated 
region of VEGF gene and UL. Accordingly, the present study 
evaluated the association between VEGF –2578 and −2549 in-
sertion/deletion polymorphisms and UL susceptibility.
In 2008, Hsieh et al. genotyped –460 polymorphism at 
5'-untranslated region of VEGF gene in 159 women with 
leiomyoma and 131 nonleiomyoma women in Taiwan, in-
dicating that VEGF –460T allele and –460TT genotype were 
associated with higher UL susceptibility.
There are several studies which have investigated the 
relation between VEGF polymorphisms and different tumors 
and cancers. Liu et al. found that −2578A allele is a protec-
tive factor against the development of endometriosis in 
Chinese women. There was an association between VEGF 
+936 C/T polymorphism, but not VEGF –460 C/T, +405 G/C 
polymorphisms and endometriosis in Tunisian population 
in the study of Henidi et al. [27]. Perini et al. showed an as-
sociation between VEGF –1154G  >  A polymorphism and the 
risk of developing endometriosis in Brazil [28].
Liu et al. found higher risk of endometriosis and adeno- 
myosis in individuals with GG genotype of VEGF –1154G/A 
Table 1. Clinical and demographic characteristics of UL women 
and control group
UL women
(n = 155)
Controls
(n = 157) p-value
Maternal age (years) 38.5 ± 9.7 38.4 ± 7.9 NS
Marriage status, n (%) 146 (94) 151 (96) NS
BMI [kg/m2] 25.8 ± 5.3 25.3 ± 4.6 NS
Age of menarche (years) 13.5 ± 1.6 13.2 ± 1.5 NS
Duration of menses (days) 6.1 ± 1.6 5.9 ± 1.6 NS
Menstrual cycle (days) 28.2 ± 3.6 28.5 ± 2.9 NS
Bleeding, n (%) 94 (61) 6 (3.8) < 0.0001
Pain, n (%) 43 (28) 10 (6.4) < 0.0001
NS — not significant; UL — uterine leiomyoma
Table 2. Comparison of genotypic and allelic frequency of VEGF 
–2578C/A polymorphism in UL women and control group
VEGF
–2578C/A
UL women
(n = 155)
Controls
(n = 157) p-value OR (95% CI)*
CC, n (%) 51 (33) 49 (31)
CA, n (%) 76 (49) 85 (54) 0.6 0.85 (0.5–1.35)
AA, n (%) 28 (18) 23 (15) 0.7 1.1 (0.8–1.5)
Allele
C, n (%) 178 (57) 183 (58)
A, n (%) 132 (43) 131 (42) 0.9
*Adjusted for age, ethnicity and primiparity 
CI — confidence interval; OR — odds ratio; UL — uterine leiomyoma;  
VEGF — vascular endothelial growth factor
Table 3. Comparison of genotypic and allelic frequency of VEGF I/D 
polymorphism in UL women and control group
VEGF
I/D poly-
morphism
UL women
(n = 155)
Controls
(n = 157)
p-value OR  
(95% CI)*
DD 44 (28.5) 46 (29) 1
ID 72 (46.5) 92 (59) 0.45 0.8 (0.5–1.4)
II 39 (25) 19 (12) 0.03 1.5 (1–2.1)
DD+ID 116 (75) 138 (88) 1
II 39 (25) 19 (12) 0.004 2.4 (1.3–4.3)
Alleles
D 160 (52) 184 (59)
I 150 (48) 130 (41) 0.09 1.3 (1–1.8)
*Adjusted for age, ethnicity and primiparity 
CI — confidence interval; OR — odds ratio; UL — uterine leiomyoma;  
VEGF — vascular endothelial growth factor
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polymorphism, however, showing no relation between 
460C/T polymorphism and these diseases [29]. The study 
of Kang et al. the –2578A or –1154A allele of VEGF gene 
significantly decreased the risk of adenomyosis and was 
considered potentially protective factor for adenomyosis 
development [30].
In a meta-analysis performed on 14 studies (3313 endo-
metriosis cases and 3393 healthy controls), Li et al. suggest-
ed that rs3025039 (+936 C/T) polymorphism of VEGF gene 
increases endometriosis risk, but VEGF-2578C/A (rs699947) 
and –1154G/A (rs1570360) polymorphisms might be protec-
tive factors for endometriosis [31].
The reason for these discrepancies remains unknown. It 
was suggested that these differences in the genotypes and 
alleles’ distribution might be due to different sample sizes 
and different selection criteria adopted for patients and 
controls in particular clinical manifestations, ethnicities, and 
environmental risk factors. Since ethnicity is a crucial factor 
in genetic studies, these differences could be more related 
to ethnic and clinical heterogeneity between populations.
In conclusion, the results showed no association be-
tween VEGF-2578C/A (rs699947) polymorphism and UL. 
However, there was a significant association between 
−2549 insertion/deletion (I/D) polymorphism in the pro-
moter region of the VEGF gene and UL. To the best of our 
knowledge, the present work is the first study regarding 
the effect of −2549 insertion/deletion (I/D) polymorphism 
of VEGF gene on UL susceptibility, and further studies are 
required to evaluate the association between VEGF poly-
morphisms and UL in different populations.
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